HealthyWay (HKSE:02587) Research & Development: HK$186 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02587 HealthyWay Inc HKSE:02587
13 GF Score
Price HK$2.11
! 1 Warning Sign
View Full Analysis

What is HealthyWay Research & Development?

HealthyWay HKSE:02587 +3.43% 13 Research & Development is HK$186 Mil as of Dec. 2025. GuruFocus rates HKSE:02587 with a GF Score™ of 13/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. HealthyWay's Research & Development for the six months ended in Dec. 2025 was HK$145 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$186 Mil.

HealthyWay  (HKSE:02587) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

HealthyWay Research & Development Related Terms

HealthyWay Research & Development Historical Data

* Premium members only.

The historical data trend for HealthyWay's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HealthyWay Research & Development Chart

HealthyWay Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
20.55 64.36 113.10 103.54 186.73

HealthyWay Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial 71.25 58.10 45.92 40.87 145.43
HKSE:02587
13GF Score
HealthyWay Inc HKSE:02587
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HealthyWay Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$186 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$186 Mil mean?
HealthyWay (HKSE:02587) has a Research & Development of HK$186 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on HealthyWay and its competitors.
Is HealthyWay's Research & Development too high?
HealthyWay's current Research & Development is HK$186 Mil. Overall, HealthyWay has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does HealthyWay's Research & Development compare to VEEV and BTSG?
HealthyWay's Research & Development of HK$186 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on HealthyWay and its competitors. HealthyWay's current Research & Development is HK$186 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthyWay stock overvalued right now?
HealthyWay (HKSE:02587) has a current Research & Development of HK$186 Mil. The current Research & Development is HK$186 Mil. HealthyWay's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For HealthyWay (HKSE:02587), the current Research & Development is HK$186 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HealthyWay Business Description

Address 89 Software Avenue, 22nd Floor, No. 3 Building, F Zone, Fuzhou Software Park, Gulou District, Fujian, Fuzhou, CHN
HealthyWay Inc operates a digital health and medical service platform in China. It has two main business segments: health and medical services; and corporate and digital marketing services. The health and medical services enable It to build an extensive connection between the supply and demand sides of the digital health and wellness market. The corporate services (especially content services) can benefit from its nationwide physician network, because it can develop corporate services that cover a wider range of medical specialties. The company generates the majority of its revenue from the corporate and digital marketing services.
13GF Score

Get the complete analysis for HKSE:02587

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.11
Price